Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?

@article{Kessler2002HaemorrhagicCO,
  title={Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?},
  author={Craig Kessler},
  journal={Intensive Care Medicine},
  year={2002},
  volume={28},
  pages={s228-s234}
}
Recombinant activated factor VII (rFVIIa, ‘NovoSeven’) is indicated for the treatment of bleeding in patients with haemophilia and inhibitors to factors VIII or IX. However, by virtue of its ability to promote thrombin generation on the platelet surface rFVIIa may also be effective in non-haemophilic bleeding, for example, in patients with thrombocytopenic or oral anticoagulant-induced haemorrhage. Studies in thrombocytopenia indicate that rFVIIa increases the generation of thrombin at the… CONTINUE READING